Tough day for ThromboGenics and BioInvent—in addition to the failure and program termination of TB-402 (#msg-76294033), former partner Roche dumped TB-403, a cancer drug targeting PIGF: http://finance.yahoo.com/news/thrombogenics-bioinvent-regain-full-rights-053200538.html